Jia Shen1, Bin Chen1, Guan-Rong Zheng1, Shen-Zhong Qiu2, Huai-Ming Yin1, Wei Mao1, Hong-Xiang Wang3, Jian-Bo Gao4. 1. Department of Neurosurgery, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China. 2. Department of Neurosurgery, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China. Electronic address: weiaanggg@163.com. 3. Department of Neurology, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China. 4. Department of Emergency Medicine, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China.
Abstract
BACKGROUND: CXC chemokine ligand-12 (CXCL12), a member of the CXC chemokine subfamily, is involved in both focal angiogenesis and inflammatory reactions. We examined serum CXCL12 concentration in intracerebral hemorrhage (ICH) patients and its correlation to stroke severity and outcome. METHODS: The study was carried out on 105 ICH patients on 105 healthy controls. Serum samples were at admission obtained to measure CXCL12 concentrations. The National Institutes of Health Stroke Scale (NIHSS) and hematoma volume were recorded to assess stroke severity. RESULTS: As compared to the controls, CXCL12 concentrations were significantly increased in the patients. Also, non-survivors within 6months and patients with an unfavorable outcome (modified Rankin Scale score>2) at 6months had higher CXCL12 concentrations than other remaining ones. CXCL12 concentrations had positive correlation with NIHSS scores and hematoma volume. Serum CXCL12 significantly discriminated patients at risk of 6-month mortality and 6-month unfavorable outcome under receiver operating characteristic curve. Moreover, serum CXCL12 was independently associated with the mortality, overall survival and unfavorable outcome. CONCLUSIONS: Serum CXCL12 concentrations are enhanced after ICH and CXCL12 in serum has the potential to reflect severity and prognosis following hemorrhagic stroke.
BACKGROUND:CXC chemokine ligand-12 (CXCL12), a member of the CXC chemokine subfamily, is involved in both focal angiogenesis and inflammatory reactions. We examined serum CXCL12 concentration in intracerebral hemorrhage (ICH) patients and its correlation to stroke severity and outcome. METHODS: The study was carried out on 105 ICHpatients on 105 healthy controls. Serum samples were at admission obtained to measure CXCL12 concentrations. The National Institutes of Health Stroke Scale (NIHSS) and hematoma volume were recorded to assess stroke severity. RESULTS: As compared to the controls, CXCL12 concentrations were significantly increased in the patients. Also, non-survivors within 6months and patients with an unfavorable outcome (modified Rankin Scale score>2) at 6months had higher CXCL12 concentrations than other remaining ones. CXCL12 concentrations had positive correlation with NIHSS scores and hematoma volume. Serum CXCL12 significantly discriminated patients at risk of 6-month mortality and 6-month unfavorable outcome under receiver operating characteristic curve. Moreover, serum CXCL12 was independently associated with the mortality, overall survival and unfavorable outcome. CONCLUSIONS: Serum CXCL12 concentrations are enhanced after ICH and CXCL12 in serum has the potential to reflect severity and prognosis following hemorrhagic stroke.